Reporter brief
The Effect of Semaglutide in Subjects With Non-cirrhotic Non-alcoholic Steatohepatitis
What happened
Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- This abstract contains no results, only study design details, so no efficacy claims can be assessed.
- The study is still ongoing (described prospectively), so outcomes remain unknown.
- No information is provided on which specific NASH endpoints (fibrosis, inflammation, liver function, or clinical events) will be measured or have been achieved.
Study design and sample
Rct; Human.
Subjects with non-cirrhotic non-alcoholic steatohepatitis (NASH). Excludes participants with other chronic liver diseases. Excludes pregnant, breast-feeding, or potentially pregnant women.
- Design
- Rct
- Sample
- —
- Journal
- Novo Nordisk A/S
- Published
- Sep 4, 2026
Effect size
Not recorded.
Caveats
- Assessment: Unassessed.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Novo Nordisk A/S (sponsor) · Study is conducted by Novo Nordisk A/S, the manufacturer of semaglutide
Previous evidence
See the GLP-1 agonists timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.